^
    Back
    Association details:
    Biomarker:TFG-ROS1 rearrangement
    Cancer:Fibrosarcoma
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Lung Cancer
    Title:

    Case report: Crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor

    Excerpt:
    The IHC assay revealed an ALK-negative tumor, while NGS detected aTFG-ROS1 rearrangement. The patient achieved continuous remission after treatment with crizotinib (250 mg, bid).
    DOI:
    10.1016/j.lungcan.2018.12.016